Puja Sapra: AstraZeneca and Cancer Research UK renew their partnership in functional genomics
Puja Sapra, Senior Vice President, Head R&D Biologics Engineering and Oncology Targeted Discovery at AstraZeneca, shared on LinkedIn:
“Delighted to share the news that, after 5 years of thriving collaboration at the Functional Genomics Centre (FGC), AstraZeneca and Cancer Research UK (CRUK)’s drug discovery engine, Cancer Research Horizons, are renewing our partnership. As part of the renewal, the FGC will move into AstraZeneca’s Discovery Centre (DISC) in Cambridge, UK, enabling even closer collaboration as we continue to work together to drive excellence in functional genomics.
This unique industry-academia partnership is working to solve some of the most pressing problems in cancer today through the development of state-of-the-art genetic screens, cancer models, CRISPR vector design, and computational approaches to big data, with a goal of identifying novel targets and resistance mechanisms to help develop new cancer medicines.
Investing in genomics is helping us to identify, interrogate and validate new targets in ways not previously thought possible. Each new insight brings us closer to creating better, more advanced and more effective treatments for people living with cancer.
Learn more about our work in functional genomics across our disease areas and our partnerships here.”
Source: Puja Sapra/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023